You need to have enough high quality data to train with, knowledge how to do it, and developer time.
In practice, that's enough of a barrier to not even try the approach on a number of cases where it might potentially be useful.
I wouldn't be surprised if Jev turned out to be a "gateway drug" that validates approach on a use case, the team gathers experience and labeled data, and switches to an in house locally tuned model to minimize costs.
In practice, that's enough of a barrier to not even try the approach on a number of cases where it might potentially be useful.
I wouldn't be surprised if Jev turned out to be a "gateway drug" that validates approach on a use case, the team gathers experience and labeled data, and switches to an in house locally tuned model to minimize costs.